NO20002698L - Cytokinlignende pattedyrpolypeptid 10 - Google Patents

Cytokinlignende pattedyrpolypeptid 10

Info

Publication number
NO20002698L
NO20002698L NO20002698A NO20002698A NO20002698L NO 20002698 L NO20002698 L NO 20002698L NO 20002698 A NO20002698 A NO 20002698A NO 20002698 A NO20002698 A NO 20002698A NO 20002698 L NO20002698 L NO 20002698L
Authority
NO
Norway
Prior art keywords
cytokine
prevention
antibody
treatment
polypeptide
Prior art date
Application number
NO20002698A
Other languages
English (en)
Other versions
NO326561B1 (no
NO20002698D0 (no
Inventor
Darrell C Conklin
Betty A Haldeman
Angelica Grossman
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20002698D0 publication Critical patent/NO20002698D0/no
Publication of NO20002698L publication Critical patent/NO20002698L/no
Publication of NO326561B1 publication Critical patent/NO326561B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
NO20002698A 1997-11-26 2000-05-26 Isolert polynukleotid som koder for et polypeptid med samme biologiske aktivitet som Zcyto10, isolert polypeptid og antistoff. NO326561B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26
PCT/US1998/025228 WO1999027103A1 (en) 1997-11-26 1998-11-25 Mammalian cytokine-like polypeptide-10

Publications (3)

Publication Number Publication Date
NO20002698D0 NO20002698D0 (no) 2000-05-26
NO20002698L true NO20002698L (no) 2000-07-20
NO326561B1 NO326561B1 (no) 2009-01-12

Family

ID=25526742

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20002698A NO326561B1 (no) 1997-11-26 2000-05-26 Isolert polynukleotid som koder for et polypeptid med samme biologiske aktivitet som Zcyto10, isolert polypeptid og antistoff.
NO20074516A NO329731B1 (no) 1997-11-26 2007-09-06 Isolert polynukleotid, ekspresjonsvektor, dyrket eukaryot eller prokaryot celle hvori ekspresjonsvektoren er innfort, fremgangsmate for fremstilling av et polypeptid, anvendelse av et isolert polypeptid for fremstilling av et antistoff som spesifikt binder til det isolerte polypeptidet, anvendelse av et polypeptid ved fremstilling av et medikament for a fremme sar-reparasjon av det trakeobronkiale epitel, eller celler som ligger under det trakeobronkiale epitel, eller for behandling av trombocytopeni, samt anvendelse av et antistoff i en diagnostisk analyse for a bestemme det sirkulerende nivaet av loselig Zcyto10-polypeptid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20074516A NO329731B1 (no) 1997-11-26 2007-09-06 Isolert polynukleotid, ekspresjonsvektor, dyrket eukaryot eller prokaryot celle hvori ekspresjonsvektoren er innfort, fremgangsmate for fremstilling av et polypeptid, anvendelse av et isolert polypeptid for fremstilling av et antistoff som spesifikt binder til det isolerte polypeptidet, anvendelse av et polypeptid ved fremstilling av et medikament for a fremme sar-reparasjon av det trakeobronkiale epitel, eller celler som ligger under det trakeobronkiale epitel, eller for behandling av trombocytopeni, samt anvendelse av et antistoff i en diagnostisk analyse for a bestemme det sirkulerende nivaet av loselig Zcyto10-polypeptid

Country Status (20)

Country Link
EP (3) EP1424393A3 (no)
JP (2) JP5191619B2 (no)
KR (1) KR100574387B1 (no)
CN (2) CN1618969A (no)
AT (1) ATE269902T1 (no)
AU (1) AU739420B2 (no)
BR (1) BR9814904A (no)
CA (1) CA2312000C (no)
CZ (1) CZ300849B6 (no)
DE (1) DE69824755T2 (no)
DK (1) DK1032671T3 (no)
EA (2) EA005581B1 (no)
ES (1) ES2218872T3 (no)
HU (1) HU227703B1 (no)
IL (2) IL136076A0 (no)
NO (2) NO326561B1 (no)
NZ (1) NZ504751A (no)
PL (2) PL198687B1 (no)
UA (2) UA86350C2 (no)
WO (1) WO1999027103A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
DE60030769T2 (de) * 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
EP1857466B1 (en) 1999-12-23 2010-10-20 ZymoGenetics, Inc. Soluble interleukin-20 receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
US7855269B2 (en) 2000-09-15 2010-12-21 Zymogenetics, Inc. Method for treating inflammation
EP1328638A2 (en) * 2000-10-20 2003-07-23 ZymoGenetics, Inc. Secreted alpha-helical protein zlmda24
EP1390060A2 (en) * 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
WO2002070001A2 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
WO2003035096A1 (en) * 2001-10-22 2003-05-01 Eli Lilly And Company Soluble proteins that inhibit cytokine signal transduction pathways
IL161978A0 (en) 2001-12-17 2005-11-20 Zymogenetics Inc Method for treating cervical cancer
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
EP2087905A2 (en) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
EP1697418A2 (en) * 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
DE602004032379D1 (de) 2003-12-19 2011-06-01 Novo Nordisk As Prozessierung von peptiden und proteinen
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
EA015706B1 (ru) 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
AU2006212807A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
CN102046808B (zh) 2008-05-27 2017-05-17 丹麦达科有限公司 使用新的杂交缓冲液用于检测染色体畸变的组合物和方法
AU2009265808B2 (en) 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
EP2340039B1 (en) * 2008-10-07 2015-11-25 National Cheng Kung University Use of il-20 antagonists for treating osteoporosis
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (en) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridization compositions and methods
BR112014021993B8 (pt) * 2012-03-05 2022-03-03 Seegene Inc "métodos para detecção de uma variação de nucleotídeo em uma sequência de ácido nucleico alvo através de um ensaio de ptoce"
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
US11279755B2 (en) 2017-04-25 2022-03-22 Lbl Biotechnology, Inc. Use of IL-20 antagonists for treating eye diseases
KR20220079651A (ko) * 2019-10-10 2022-06-13 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 진통 및 마취 펩티드 및 기타 제제
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424410T1 (de) * 1996-08-30 2009-03-15 Human Genome Sciences Inc Interleukin-19.
DE60030769T2 (de) * 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen

Also Published As

Publication number Publication date
PL340755A1 (en) 2001-02-26
DE69824755D1 (de) 2004-07-29
UA73275C2 (en) 2005-07-15
BR9814904A (pt) 2000-10-03
EP1424393A3 (en) 2004-06-09
NZ504751A (en) 2001-10-26
HU227703B1 (en) 2011-12-28
EP1032671B1 (en) 2004-06-23
EA200000565A1 (ru) 2000-12-25
HUP0100436A3 (en) 2003-08-28
PL198687B1 (pl) 2008-07-31
WO1999027103A1 (en) 1999-06-03
IL136076A0 (en) 2001-05-20
EP1719780A3 (en) 2006-12-20
KR20010032490A (ko) 2001-04-25
KR100574387B1 (ko) 2006-04-27
PL195304B1 (pl) 2007-08-31
NO329731B1 (no) 2010-12-13
CZ20001910A3 (cs) 2000-11-15
CZ300849B6 (cs) 2009-08-26
ES2218872T3 (es) 2004-11-16
EP1032671A1 (en) 2000-09-06
CN1247780C (zh) 2006-03-29
EA005581B1 (ru) 2005-04-28
AU1607799A (en) 1999-06-15
DK1032671T3 (da) 2004-10-11
UA86350C2 (en) 2009-04-27
JP5331054B2 (ja) 2013-10-30
EP1424393A2 (en) 2004-06-02
CN1618969A (zh) 2005-05-25
NO326561B1 (no) 2009-01-12
JP5191619B2 (ja) 2013-05-08
CN1282372A (zh) 2001-01-31
JP2010187698A (ja) 2010-09-02
CA2312000C (en) 2013-03-26
ATE269902T1 (de) 2004-07-15
NO20002698D0 (no) 2000-05-26
NO20074516L (no) 2000-07-20
AU739420B2 (en) 2001-10-11
IL136076A (en) 2007-12-03
EP1719780A2 (en) 2006-11-08
CA2312000A1 (en) 1999-06-03
EA010741B1 (ru) 2008-10-30
EA200401501A1 (ru) 2006-02-24
DE69824755T2 (de) 2005-08-04
HUP0100436A2 (hu) 2001-06-28
JP2001524313A (ja) 2001-12-04

Similar Documents

Publication Publication Date Title
DK1032671T3 (da) Mammalt cytokin-lignende polypeptid-10
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
EP1466925A4 (en) ANTIBODIES TO THE FIBROBLAST GROWTH FACTOR 23
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
DE59710091D1 (de) Von Kaposi-sarkom assoziiertem Herpes-Virus (KSHV, HHV-8) kodiertes Polypeptid und dessen Verwendung in Diagnostik und Therapie
ATE366810T1 (de) Menschliche p51-gene und deren genprodukte
DE69433221D1 (de) Neues Chondrozytprotein
KR950704352A (ko) 테라포시데 아포노펠마로부터의 칼슘 통로 차단 폴리펩티드(calcium channel blocking polypeptides from theraphosidae aphonopelma)
DE60325227D1 (no)
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
EP0749981A4 (en) MONOCLONAL ANTIBODY
KR930019827A (ko) 신규 폴리펩티드 및 이를 암호하는 dna
MX9504057A (es) Proteina que tiene actividad tpo.
NZ606260A (en) Novel polypeptides involved in immune response
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees